FI954699L - MSRV1-virus ja multippeliskleroosiin liittyvä patogeeninen ja/tai infektoiva MSRV2-agenssi, niiden nukleiinihappokomponentteja ja niiden sovellutuksia - Google Patents

MSRV1-virus ja multippeliskleroosiin liittyvä patogeeninen ja/tai infektoiva MSRV2-agenssi, niiden nukleiinihappokomponentteja ja niiden sovellutuksia Download PDF

Info

Publication number
FI954699L
FI954699L FI954699A FI954699A FI954699L FI 954699 L FI954699 L FI 954699L FI 954699 A FI954699 A FI 954699A FI 954699 A FI954699 A FI 954699A FI 954699 L FI954699 L FI 954699L
Authority
FI
Finland
Prior art keywords
msrv1
msrv2
pathogenic
virus
applications
Prior art date
Application number
FI954699A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI954699A0 (fi
FI954699A7 (fi
Inventor
Herve Perron
Francois Mallet
Bernard Mandrand
Frederic Bedin
Frederic Beseme
Original Assignee
Bio Merieux
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9401532A external-priority patent/FR2715937A1/fr
Priority claimed from FR9401530A external-priority patent/FR2715938B1/fr
Priority claimed from FR9401531A external-priority patent/FR2715939B1/fr
Priority claimed from FR9401529A external-priority patent/FR2715936B1/fr
Priority claimed from FR9414322A external-priority patent/FR2727428B1/fr
Priority claimed from FR9415810A external-priority patent/FR2728585A1/fr
Application filed by Bio Merieux filed Critical Bio Merieux
Publication of FI954699A0 publication Critical patent/FI954699A0/fi
Publication of FI954699L publication Critical patent/FI954699L/fi
Publication of FI954699A7 publication Critical patent/FI954699A7/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/911—Microorganisms using fungi
    • Y10S435/912—Absidia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
FI954699A 1994-02-04 1995-02-06 MSRV1-virus ja multippeliskleroosiin liittyvä patogeeninen ja/tai infe ktoiva MSRV2-agenssi, niiden nukleiinihappokomponentteja ja niiden sov ellutuksia FI954699A7 (fi)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
FR9401532A FR2715937A1 (fr) 1994-02-04 1994-02-04 Virus MSRV1 et MSRV2 associés ensemble à la sclérose en plaques et leurs constituants nucléiques.
FR9401530A FR2715938B1 (fr) 1994-02-04 1994-02-04 Constituants nucléiques du virus MSRV1, associé à la sclérose en plaques.
FR9401531A FR2715939B1 (fr) 1994-02-04 1994-02-04 Virus MSRV2 associé à la sclérose en plaques, et ses constituants nucléiques.
FR9401529A FR2715936B1 (fr) 1994-02-04 1994-02-04 Virus MSRV1 associé à la sclérose en plaques, et ses constituants nucléiques.
FR9414322A FR2727428B1 (fr) 1994-11-24 1994-11-24 Virus msrv1 associe a la sclerose en plaques et ses constituants nucleiques
FR9415810A FR2728585A1 (fr) 1994-12-23 1994-12-23 Virus msrv1 et agent pathogene et/ou infectant msrv2 associes a la sclerose en plaques et leurs constituants nucleiques
PCT/FR1995/000142 WO1995021256A1 (fr) 1994-02-04 1995-02-06 Virus msrv1 et agent pathogene et/ou infectant msrv2 associes a la sclerose en plaques, leurs constituants nucleiques et leurs applications

Publications (3)

Publication Number Publication Date
FI954699A0 FI954699A0 (fi) 1995-10-03
FI954699L true FI954699L (fi) 1995-10-03
FI954699A7 FI954699A7 (fi) 1995-10-03

Family

ID=27546415

Family Applications (1)

Application Number Title Priority Date Filing Date
FI954699A FI954699A7 (fi) 1994-02-04 1995-02-06 MSRV1-virus ja multippeliskleroosiin liittyvä patogeeninen ja/tai infe ktoiva MSRV2-agenssi, niiden nukleiinihappokomponentteja ja niiden sov ellutuksia

Country Status (12)

Country Link
US (6) US5871996A (de)
EP (1) EP0674004B1 (de)
JP (1) JP3611856B2 (de)
AT (1) ATE285475T1 (de)
AU (1) AU704440B2 (de)
CA (1) CA2141907A1 (de)
DE (2) DE674004T1 (de)
ES (1) ES2233936T3 (de)
FI (1) FI954699A7 (de)
NO (1) NO953925L (de)
NZ (1) NZ279855A (de)
WO (1) WO1995021256A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5871996A (en) 1994-02-04 1999-02-16 Bio Merieux Retrovirus agents MSRV1 and MSRV2 associated with multiple sclerosis
FR2731356B1 (fr) * 1995-03-09 1997-04-30 Bio Merieux Virus msrv-1 et agent pathogene et/ou infectant msrv-2 associes a la polyarthrite rhumatoide
FR2737500B1 (fr) * 1995-08-03 1997-08-29 Bio Merieux Materiel viral et fragments nucleotidiques associes a la sclerose en plaques, a des fins de diagnostic, prophylactiques et therapeutiques
US6771381B1 (en) 1998-11-13 2004-08-03 Laurence C. Klein Distributed computer architecture and process for virtual copying
EP0942987B1 (de) * 1996-11-26 2009-08-19 Bio Merieux Virales material und mit multipler sklerose assoziierte nukleotidfragmente mit diagnostischen, prophylaktischen und therapeutischen verwendungen
EP0887070B1 (de) * 1997-05-30 2004-12-22 Kibun Food ChemiFA Co., Ltd. Äusserliches Haupflegemittel enthaltend ein Sphingoglycolipid
FR2765588A1 (fr) 1997-07-07 1999-01-08 Bio Merieux Materiel nucleique retroviral et fragments nucleotidiques notamment associes a la sclerose en plaques et/ou la polyarthrite rhumatoide, a des fins de diagnostic, prophylactiques et therapeutiques
US20070067859A1 (en) * 1997-07-14 2007-03-22 Michel Georges Double-muscling in mammals
DE69841139D1 (de) * 1997-07-14 2009-10-22 Univ Liege Mutationen im myostatingen steigern muskelmasse in säugetieren
US6103466A (en) * 1997-07-14 2000-08-15 University Of Liege Double-muscling in mammals
EP1068361A1 (de) * 1998-04-08 2001-01-17 MS Research A/S Diagnose von multipler sklerose und anderen demyelinierenden krankheiten
FR2780069B1 (fr) * 1998-06-23 2002-06-28 Inst Nat Sante Rech Med Famille de sequences nucleiques et de sequences proteiques deduites presentant des motifs retroviraux endogenes humains et leurs applications
FR2788784A1 (fr) * 1999-01-21 2000-07-28 Bio Merieux Fragment nucleique endogene associe a une maladie auto-immune, procede de marquage et reactif
EP1029917A1 (de) 1999-02-15 2000-08-23 Bio Merieux Die LTR-Region von MSRV und die durch sie kodierten Proteine, und Sonden und Methoden für Detektion des MSRV-1 Retrovirus
US6787303B1 (en) 1999-04-01 2004-09-07 Alton Ochsner Medical Foundation Identification of a novel retrovirus associated with primary sclerosing cholangitis and autoimmune hepatitis
AU4187400A (en) * 1999-04-01 2000-10-23 Alton Ochsner Medical Foundation Retrovirus associated with primary sclerosing cholangitis
DE19921419A1 (de) 1999-05-08 2000-11-16 Univ Ruprecht Karls Heidelberg Verfahren zum spezifischen Nachweis und zur Identifizierung retroviraler Nukleinsäuren / Retroviren in einem Untersuchungsgut
WO2003066661A2 (en) * 2001-07-03 2003-08-14 Genentech, Inc. Human dr4 antibodies and uses thereof
WO2003016546A1 (en) * 2001-08-21 2003-02-27 Flinders Technologies Pty Ltd. Method and device for simultaneously molecularly cloning and polylocus profiling of genomes or genome mixtures
FR2865403B1 (fr) * 2004-01-23 2009-06-12 Biomerieux Sa Composition pour le traitement d'une pathologie associee a la msrv/herv-w
PL1774037T3 (pl) * 2004-08-06 2011-09-30 Genentech Inc Oznaczenia i sposoby wykorzystujące biomarkery
MX2007001469A (es) * 2004-08-06 2007-03-26 Genentech Inc Ensayos y metodos que utilizan biomarcadores.
KR20070050951A (ko) * 2004-09-08 2007-05-16 제넨테크, 인크. 사멸 수용체 리간드 및 ｃｄ20 항체의 사용 방법
BRPI0515615A (pt) * 2004-09-08 2008-07-29 Genentech Inc métodos para tratar células cancerosas e doença imune relacionada
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US8029783B2 (en) * 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
JP5186372B2 (ja) 2005-08-16 2013-04-17 ジェネンテック， インコーポレイテッド 細胞／組織においてｇａｌｎａｃ−ｔ１４発現を試験することによるａｐｏ２ｌ／ｔｒａｉｌに対するアポトーシス感受性
US8680065B2 (en) * 2008-09-11 2014-03-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Oligonucleotides of human endogenous retrovirus 9 (ERV-9) long terminal repeat (LTR) and methods of use
US20140178398A1 (en) 2011-05-03 2014-06-26 Genentech, Inc Vascular disruption agents and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5871996A (en) 1994-02-04 1999-02-16 Bio Merieux Retrovirus agents MSRV1 and MSRV2 associated with multiple sclerosis
WO1980000412A1 (en) * 1978-08-24 1980-03-20 N Gilmour Pasteurellosis vaccines
US4311686A (en) * 1979-04-30 1982-01-19 The Immunology Development Corporation Methodology for the immunodiagnosis of multiple sclerosis and/or malignant diseases from blood sample analysis
US4396600A (en) * 1980-12-18 1983-08-02 Gus Gallucci Adult schistosome worm-derived antigenic substance and method of obtaining same
US4388298A (en) * 1982-07-14 1983-06-14 The United States Of America As Represented By The Secretary Of Agriculture Propagation of hemorrhagic enteritis virus in a turkey cell line and vaccine produced
GB8324800D0 (en) * 1983-09-15 1983-10-19 Pasteur Institut Antigens
US4520113A (en) * 1984-04-23 1985-05-28 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Serological detection of antibodies to HTLV-III in sera of patients with AIDS and pre-AIDS conditions
US4647773A (en) * 1984-04-23 1987-03-03 The United States Of America As Represented By The Department Of Health And Human Services Method of continuous production of retroviruses (HTLV-III) from patients with AIDS and pre-AIDS
NZ218050A (en) * 1985-11-13 1989-05-29 Wistar Inst Test for the presence of htlv-1v
US4900553A (en) * 1987-09-11 1990-02-13 Case Western Reserve University Method of reducing glial scar formation and promoting axon and blood vessel growth and/or regeneration through the use of activated immature astrocytes
EP0326395A2 (de) * 1988-01-29 1989-08-02 City Of Hope Verfahren zum Nachweis und zur Identifizierung von bestimmten viralen Sequenzien
FR2651581B1 (fr) * 1989-09-06 1994-05-13 Centre Nal Recherc Scientifique Moyens pour le diagnostic de neuropathies demyelinisantes, en particulier de la sclerose en plaques.
US5219837A (en) * 1990-06-21 1993-06-15 Trustees Of The University Of Pennsylvania Method of stimulating myelination of cells
US5158976A (en) * 1990-10-29 1992-10-27 The Children's Medical Center Corporation Controlling glutamine/glutamate related neuronal injury
DK173091D0 (da) * 1991-10-11 1991-10-11 Schleroseforeningen The Danish Biologisk materiale
FR2689521B1 (fr) * 1992-04-03 1996-07-19 Bio Merieux Procede d'obtention et maintien d'une culture cellulaire viable, infectee par un virus associe a la sclerose en plaques, et produits biologiques derives de ladite culture.
FR2689520B1 (fr) 1992-04-03 1996-07-19 Bio Merieux Procede et milieu de culture pour l'obtention de cellules infectees par un virus associe a la sclerose en plaques.
DK0642585T3 (da) * 1992-05-18 2006-05-15 Genentech Inc Aktiviering af oligomeriserende receptorer ved anvendelse af fusionerede receptorligander
GB9310657D0 (en) * 1993-05-24 1993-07-07 Univ London Retrovirus
FR2716198B1 (fr) 1994-02-15 1996-04-19 Bio Merieux Facteur cytotoxique tel qu'associé à la sclérose en plaques, sa détection et sa quantification.

Also Published As

Publication number Publication date
US5871996A (en) 1999-02-16
JPH08511170A (ja) 1996-11-26
US6184025B1 (en) 2001-02-06
NO953925L (no) 1995-12-04
US5800980A (en) 1998-09-01
CA2141907A1 (fr) 1995-08-05
DE69533863T2 (de) 2006-02-16
DE674004T1 (de) 1996-09-19
JP3611856B2 (ja) 2005-01-19
ATE285475T1 (de) 2005-01-15
EP0674004A1 (de) 1995-09-27
FI954699A0 (fi) 1995-10-03
US6342383B1 (en) 2002-01-29
NO953925D0 (no) 1995-10-03
EP0674004B1 (de) 2004-12-22
AU704440B2 (en) 1999-04-22
US5871745A (en) 1999-02-16
WO1995021256A1 (fr) 1995-08-10
DE69533863D1 (de) 2005-01-27
NZ279855A (en) 1998-05-27
ES2233936T3 (es) 2005-06-16
AU1711495A (en) 1995-08-21
US5962217A (en) 1999-10-05
FI954699A7 (fi) 1995-10-03

Similar Documents

Publication Publication Date Title
FI954699L (fi) MSRV1-virus ja multippeliskleroosiin liittyvä patogeeninen ja/tai infektoiva MSRV2-agenssi, niiden nukleiinihappokomponentteja ja niiden sovellutuksia
ID27457A (id) Komposisi untuk pengobatan hiv dan infeksi virus lainnya
FI970115L (fi) Nukeliinihappoja sisältävä valmiste, sen valmistus ja käytöt
FI962799A7 (fi) Nukleiinihappoja sisältävä valmiste, sen valmistus ja käyttö
NO954217D0 (no) Guanosinrike antivirus-oligonukleotider
FI971823L (fi) Katalyyttikoostumus ja olefiinin polymerointiprosessi
FI955224L (fi) Hepatiitti-C-virustyypit 4,5 ja 6
DE69431222D1 (de) Übergangsmetallverbindung, und diese enthaltender Polymerisationkatalysator
DK149194A (da) Thrombopoietin
FI963183A7 (fi) Vesipitoinen dispersiokoostumus, ja sitä käyttävä koostumus
FI970094L (fi) Substituoidut bentsamidiinit, niiden valmistus ja käyttö lääkeaineena
BR9509784A (pt) Processo térmico de polimerização de metátase e composição polimerizável
FI972110L (fi) Kantaja-aineella oleva katalyyttikomponentti, kantaja-aineella oleva katalyytti, niiden valmistus ja additiopolymerointimenetelmä
FI945221L (fi) Yhdistelmä-DNA-molekyylejä, jotka koodittavat aminopeptidaasientsyymejä, ja niiden käyttö rokotteiden valmistamiseksi matotartuntoja vastaan
NO993353D0 (no) Tverr- og aksialarmerte pultruderingsprodukter
FI944700A7 (fi) Kromikatalyyttikoostumukset ja niillä polymerointimenetelmät
DE69405153D1 (de) Mikrokanalplatten
FI972192A0 (fi) Imino-oksimetyleenianilidit, menetelmät ja välituotteet niiden valmistamiseksi ja niitä sisältävät tuholaistentorjunta-aineet
FI961202L (fi) Grb3-3-geeni, sen variantteja ja niiden käyttöjä
NO954880D0 (no) Cytidin deaminase
FI971817A7 (fi) Tartuntaelin
BR9400338A (pt) Processo para preparação de 1,1,1,2-tetrafluoro-2-cloroetano e de pentafluoretano
FI912223A7 (fi) Katalyyttikoostumuksia ja polymerointimenetelmä, heksakisfosfiineja ja heksahalogeeniyhdisteitä
FI954876L (fi) Hajapesäkkeiseen skleroosiin liittyvä sytoksinen tekijä, sen havaitseminen ja kvantitointi
NO964760D0 (no) MSRV-1-virus og patogent og/eller infeksiöst MSRV-2-middel forbundet med reumatoid artritt